Skip to main content
SpringerLink
Log in

Comment on: “Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis”

  • Letter to the Editor
  • Published:
CNS Drugs Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 26 February 2019

The Original Article was published on 01 August 2018

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Papadopoulos D, Mitsikostas DD. Oral disease-modifying treatments for relapsing multiple sclerosis: a likelihood to achieve no evidence of disease activity or harm analysis. CNS Drugs. 2018;32(11):1069–78. https://doi.org/10.1007/s40263-018-0547-z.

    Article  CAS  PubMed  Google Scholar 

  2. Giovannoni G, Comi G, Cook S, CLARITY Study Group, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416–26.

  3. Gold R, Kappos L, Arnold DL, DEFINE Study Investigators, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098–107.

  4. Fox RJ, Miller DH, Phillips JT, CONFIRM Study Investigators, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087–97.

  5. Kappos L, Radue E-W, O’Connor P, FREEDOMS Study Group, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401.

  6. Calabresi PA, Radue E-W, Goodin D, Jeffery D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMSII): a double-blind, randomized, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:545–56.

    Article  CAS  Google Scholar 

  7. O’Connor P, Wolinsky JS, Confavreux C, TEMSO Trial Group, et al. Randomised trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293–303.

  8. Havrdova E, Giovannoni G, Gold R, et al. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies. Eur J Neurol. 2017;24:726–33.

    Article  CAS  Google Scholar 

  9. Kappos L, De Stefano N, Freedman MS, et al. Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing-remitting multiple sclerosis. Mult Scler J. 2016;22:1297–305.

    Article  Google Scholar 

  10. Giovannoni G, Cook S, Rammohan K, CLARITY Study Group, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post hoc and subgroup analysis. Lancet Neurol. 2011;10:329–37.

  11. Freedman M, O’Connor P, Wolinsky J, et al. Teriflunomide increases the proportion of patients free from disease activity in the TEMSO phase III study. Neurology. 2012;78(Suppl.):PD5.007.

  12. Tsivgoulis G, Katsanos AH, Voumvourakis K, et al. Commentary on: Comparing the efficacy of disease-modifying therapies in multiple sclerosis. Mult Scler Relat Dis. 2018;21:117–9.

    Article  Google Scholar 

  13. Hutton JL. Number needed to treat: properties and problems. J R Stat Soc Ser A. 2000;63:403–19.

    Google Scholar 

  14. Hutton JL. Misleading statistics: the problems surrounding number needed to treat and number needed to harm. Pharm Med. 2010;24:145–9.

    Article  Google Scholar 

  15. Mavridis D, Giannatsi M, Cipriani A, Salanti G. A primer on network meta-analysis with emphasis on mental health. Evid Based Ment Health. 2015;18:40–6.

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank the Hellenic Academy of Neuroimmunology (HELANI) for supporting their research with an unrestricted grant for publication fees.

Author information

Authors and Affiliations

  1. Second Department of Neurology, “Attikon” Hospital, School of Medicine, National and Kapodistrian University of Athens, Iras 39, Gerakas Attikis, Athens, 15344, Greece

    Georgios Tsivgoulis, Lina Palaiodimou, Aristeidis H. Katsanos & Konstantinos Voumvourakis

  2. Department of Neurology, University of Tennessee Health Science Center, Memphis, TN, USA

    Georgios Tsivgoulis

  3. Department of Neurology, School of Medicine, University of Ioannina, Ioannina, Greece

    Aristeidis H. Katsanos

  4. Department of Neurology, University Hospital of Larissa, University of Thessaly, Larissa, Greece

    Georgios M. Hadjigeorgiou

  5. Department of Neurology, Alexandroupolis University Hospital, Democritus University of Thrace, Alexandroupolis, Greece

    Ioannis Heliopoulos

  6. Second Department of Neurology, “AHEPA” University Hospital, Aristotelion University of Thessaloniki, Thessaloniki, Macedonia, Greece

    Theodore Karapanayiotides & Nikolaos Grigoriadis

  7. Department of Neurology, University of Patras Medical School, Patras, Greece

    Panagiotis Papathanasopoulos

  8. First Department of Neurology, “Eginition” Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

    Constantinos Kilidireas

Authors
  1. Georgios Tsivgoulis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lina Palaiodimou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aristeidis H. Katsanos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Konstantinos Voumvourakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Georgios M. Hadjigeorgiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ioannis Heliopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Theodore Karapanayiotides
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Panagiotis Papathanasopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Constantinos Kilidireas
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Nikolaos Grigoriadis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Georgios Tsivgoulis.

Ethics declarations

Funding

Georgios Tsivgoulis has received research support (not related to this project) from Teva Pharmaceutical Hellas, Genesis Pharma, and Novartis Hellas. Konstantinos Voumvourakis has received research support (not related to this project) from Teva Pharmaceutical Hellas, Merck Hellas, Genesis Pharma, and Novartis Hellas. Panagiotis Papathanasopoulos has received research support (not related to this project) from Biogen Idec, Novartis, TEVA, Merck Serono, and Genesis Pharma. Nikolaos Grigoriadis has received research support (not related to this project) from Biogen Idec, Novartis, TEVA, Merck Serono, and Genesis Pharma. Lina Palaiodimou, Aristeidis H. Katsanos, Georgios M. Hadjigeorgiou, Ioannis Heliopoulos, Theodore Karapanayiotides, and Constantinos Kilidireas report no sources of funding. The funding sources mentioned above had no role in the decision to publish, or the preparation of the present letter.

Conflict of interest

Georgios Tsivgoulis, Lina Palaiodimou, Aristeidis H. Katsanos, Konstantinos Voumvourakis, Georgios M. Hadjigeorgiou, Ioannis Heliopoulos, Theodore Karapanayiotides, Panagiotis Papathanasopoulos, Constantinos Kilidireas, and Nikolaos Grigoriadis have no conflicts of interest that are directly relevant to the content of this letter.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tsivgoulis, G., Palaiodimou, L., Katsanos, A.H. et al. Comment on: “Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis”. CNS Drugs 33, 293–295 (2019). https://doi.org/10.1007/s40263-019-00615-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-019-00615-5

Search

Navigation